Payment overview · 2025
General Payments
$809.11
43 reported records · 13 companies
Healthcare provider profile · identity verified
Jason Tyler Given, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ROCK HILL, SC · NPI 1275739922
Verified facts
What the public records show
CMS Open Payments records show Jason Tyler Given, M.D. received $809.11 in general payments during 2025 across 43 reported records.
ABBVIE INC. accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $170.03 | 21.0% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $122.57 | 15.2% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $84.84 | 10.5% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $80.52 | 9.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $74.31 | 9.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $69.67 | 8.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $59.73 | 7.4% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $55.27 | 6.8% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $33.98 | 4.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.22 | 2.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.42 | 1.8% | 1 | 2025 |
| PhotoniCare Inc | Unresolved — no canonical attribution shown | $13.94 | 1.7% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.61 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $809.11 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $125.63 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $125.63 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $122.57 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $84.84 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $84.84 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $80.52 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $69.67 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $69.67 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $55.27 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.71 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $54.71 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $45.07 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $44.40 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $33.98 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| OtoSight Middle Ear Scope Normalized: otosight middle ear scope |
Device | PhotoniCare Inc | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 45 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 58 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 493 | 130 |
| Prednisone | Prednisone | 306 | 231 |
| Amlodipine Besylate | Amlodipine Besylate | 303 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 301 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 299 | 81 |
| Losartan Potassium | Losartan Potassium | 267 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 240 | 65 |
| Lisinopril | Lisinopril | 235 | 66 |
| Tramadol Hcl | Tramadol Hcl | 235 | 63 |
| Alprazolam | Alprazolam | 203 | 34 |
| Gabapentin | Gabapentin | 203 | 72 |
| Meloxicam | Meloxicam | 171 | 56 |
| Trazodone Hcl | Trazodone Hcl | 168 | 40 |
| Omeprazole | Omeprazole | 163 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 155 | 71 |
| Simvastatin | Simvastatin | 147 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 144 | 51 |
| Metformin Hcl | Metformin Hcl | 136 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 25 |
| Glipizide | Glipizide | 116 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 32 |
| Potassium Chloride | Potassium Chloride | 110 | 35 |
| Cefdinir | Cefdinir | 108 | 94 |
| Furosemide | Furosemide | 108 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 105 | 31 |
| Montelukast Sodium | Montelukast Sodium | 104 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 102 | 26 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 102 | 94 |
| Bupropion Xl | Bupropion Hcl | 101 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 98 | 21 |
| Clonazepam | Clonazepam | 91 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 91 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 37 |
| Sertraline Hcl | Sertraline Hcl | 87 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 38 |
| Spironolactone | Spironolactone | 80 | 24 |
| Allopurinol | Allopurinol | 77 | 22 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 73 | 65 |
| Ozempic | Semaglutide | 73 | 18 |
| Famotidine | Famotidine | 72 | 32 |
| Naproxen | Naproxen | 72 | 33 |
| Cephalexin | Cephalexin | 71 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 24 |
| Carvedilol | Carvedilol | 68 | 20 |
| Chlorthalidone | Chlorthalidone | 60 | 17 |
| Mounjaro | Tirzepatide | 58 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 16 |
| Lorazepam | Lorazepam | 57 | 17 |
| Lovastatin | Lovastatin | 57 | 15 |
| Synthroid | Levothyroxine Sodium | 57 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | 13 |
| Benazepril Hcl | Benazepril Hcl | 54 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 13 |
| Etodolac | Etodolac | 53 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | 12 |
| Methocarbamol | Methocarbamol | 48 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 23 |
| Farxiga | Dapagliflozin Propanediol | 45 | 13 |
| Januvia | Sitagliptin Phosphate | 45 | suppressed |
| Torsemide | Torsemide | 45 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | 24 |
| Ezetimibe | Ezetimibe | 42 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 12 |
| Buspirone Hcl | Buspirone Hcl | 41 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 17 |
| Valacyclovir | Valacyclovir Hcl | 37 | 12 |
| Azithromycin | Azithromycin | 36 | 36 |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Fluconazole | Fluconazole | 36 | 30 |
| Jardiance | Empagliflozin | 35 | 12 |
| Topiramate | Topiramate | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Mupirocin | Mupirocin | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 31 |
| Nystatin | Nystatin | 31 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Eliquis | Apixaban | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 18 |
| Dexamethasone | Dexamethasone | 23 | 21 |
| Diazepam | Diazepam | 23 | 11 |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 18 |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 15 |
| Testosterone | Testosterone | 21 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 20 | 19 |
| Temazepam | Temazepam | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Indomethacin | Indomethacin | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Tobramycin | Tobramycin | 17 | 17 |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Fluorouracil | Fluorouracil | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $809.11 · 43 records | ABBVIE INC. | AIRSUPRA, AZMIRO, CAPLYTA, FARXIGA, FREESTYLE LIBRE 3, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, OtoSight Middle Ear Scope, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error